Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Zenas Biopharma Inc ZBIO

Healthcare Biotechnology
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on the development and commercialization of transformative therapies for patients with autoimmune diseases. The Company's lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are broadly present across B cell lineage, to inhibit the activity of... see more

Recent & Breaking News (NDAQ:ZBIO)

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zenas BioPharma, Inc. (ZBIO) and Encourages Shareholders to Learn More About the Investigation

ACCESS Newswire 2 days ago

Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire 4 days ago

Zenas BioPharma, Inc. (ZBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

ACCESS Newswire 4 days ago

Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences

GlobeNewswire 5 days ago

Zenas BioPharma, Inc. (ZBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

ACCESS Newswire 6 days ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Zenas BioPharma, Inc. (ZBIO) And Encourages Investors to Connect

ACCESS Newswire 9 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages Zenas BioPharma, Inc. (ZBIO) Stockholders to Inquire about Securities Investigation

ACCESS Newswire 11 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zenas BioPharma, Inc. (ZBIO) and Encourages Investors to Learn More About the Investigation

ACCESS Newswire 13 days ago

Zenas BioPharma, Inc. (ZBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

ACCESS Newswire October 30, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Zenas BioPharma, Inc. (ZBIO) And Encourages Stockholders to Reach Out

ACCESS Newswire October 28, 2025

Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis

GlobeNewswire October 27, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Zenas BioPharma, Inc. (ZBIO) And Encourages Stockholders to Connect

ACCESS Newswire October 26, 2025

Zenas BioPharma, Inc. (ZBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

ACCESS Newswire October 23, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zenas BioPharma, Inc. (ZBIO) and Encourages Stockholders to Learn More About the Investigation

ACCESS Newswire October 21, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Zenas BioPharma, Inc. (ZBIO) Investors to Inquire about Securities Investigation

ACCESS Newswire October 19, 2025

Zenas BioPharma, Inc. (ZBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

ACCESS Newswire October 12, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Zenas BioPharma, Inc. (ZBIO) Shareholders to Inquire about Securities Investigation

ACCESS Newswire October 9, 2025

Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis

GlobeNewswire October 8, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Zenas BioPharma, Inc. (ZBIO) And Encourages Investors to Connect

ACCESS Newswire October 5, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zenas BioPharma, Inc. (ZBIO) and Encourages Investors to Learn More About the Investigation

ACCESS Newswire September 30, 2025